FGP
MYGN icon

Freestone Grove Partners’s Myriad Genetics MYGN Stock Holding History

Freestone Grove Partners’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6 Buy
+1
New +$5 ﹤0.01% 979

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Freestone Grove Partners's MYGN Position: Q2 2026 in Review

Freestone Grove Partners opened a new position in Myriad Genetics (MYGN) in Q2 2026: 1 share worth $6. The stake represents ﹤0.01% of the portfolio and ranks #979 among its holdings.

196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Freestone Grove Partners held 1 share of Myriad Genetics worth $6 as of Q2 2026.
  • Myriad Genetics was a new Freestone Grove Partners position in Q2 2026.
  • Myriad Genetics made up ﹤0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #979 holding.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.